The Gut Microbiota and Liver Disease

Cellular and Molecular Gastroenterology and Hepatology

Volumn 1, Issue 3, 2015, Pages 275-284

  Llorente, Cristina ^a,b   Schnabl, Bernd ^a,b  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

Author keywords

Alcoholic liver disease; Cirrhosis; Dysbiosis; Leaky gut; Microbiome; NAFLD; NASH; PAMPs

Indexed keywords

ADENOSINE PHOSPHATE; ANTIBIOTIC AGENT; CASPASE RECRUITMENT DOMAIN PROTEIN 15; IMMUNOGLOBULIN A; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 18; INTERLEUKIN 1BETA; METALLOPROTEINASE; MYELOID DIFFERENTIATION FACTOR 88; PROGRAMMED DEATH 1 RECEPTOR; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA;

ALCOHOL CONSUMPTION; ALCOHOL LIVER DISEASE; BACTERIAL OVERGROWTH; BIFIDOBACTERIUM; CHRONIC LIVER DISEASE; CLINICAL TRIAL (TOPIC); CLOSTRIDIALES; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; DYSBIOSIS; END STAGE LIVER DISEASE; ENDOTOXEMIA; ENVIRONMENTAL FACTOR; GENE LOCUS; GENETIC POLYMORPHISM; HEREDITY; HUMAN; IMMUNE SYSTEM; INTESTINE FLORA; LIVER CIRRHOSIS; LIVER DISEASE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SYMBIOSIS; T LYMPHOCYTE;

EID: 84929248841     PISSN: None     EISSN: 2352345X     Source Type: Journal    
DOI: 10.1016/j.jcmgh.2015.04.003     Document Type: Review

References (117)

1. Qin J., Li R., Raes J., et al. Ahuman gut microbial gene catalogue established by metagenomic sequencing. Nature 2010, 464:59-65.
2. Sonnenburg J.L., Xu J., Leip D.D., et al. Glycan foraging invivo by an intestine-adapted bacterial symbiont. Science 2005, 307:1955-1959.
3. Yatsunenko T., Rey F.E., Manary M.J., et al. Human gut microbiome viewed across age and geography. Nature 2012, 486:222-227.
4. Olszak T., An D., Zeissig S., et al. Microbial exposure during early life has persistent effects on natural killer T cell function. Science 2012, 336:489-493.
5. Uematsu S., Fujimoto K., Jang M.H., et al. Regulation of humoral and cellular gut immunity by lamina propria dendritic cells expressing Toll-like receptor 5. Nat Immunol 2008, 9:769-776.
6. Ley R.E., Turnbaugh P.J., Klein S., et al. Microbial ecology: human gut microbes associated with obesity. Nature 2006, 444:1022-1023.
7. Kau A.L., Ahern P.P., Griffin N.W., et al. Human nutrition, the gut microbiome and the immune system. Nature 2011, 474:327-336.
8. Frank D.N., St Amand A.L., Feldman R.A., et al. Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proc Natl Acad Sci USA 2007, 104:13780-13785.
9. Hsiao E.Y., McBride S.W., Hsien S., et al. Microbiota modulate behavioral and physiological abnormalities associated with neurodevelopmental disorders. Cell 2013, 155:1451-1463.
10. Yoshimoto S., Loo T.M., Atarashi K., et al. Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome. Nature 2013, 499:97-101.
11. Schnabl B. Transplanting a fibrogenic microbiota. Hepatology 2014, 59:1660-1661.
12. Hartmann P., Chen P., Wang H.J., et al. Deficiency of intestinal mucin-2 ameliorates experimental alcoholic liver disease in mice. Hepatology 2013, 58:108-119.
13. Grivennikov S.I., Wang K., Mucida D., et al. Adenoma-linked barrier defects and microbial products drive IL-23/IL-17-mediated tumour growth. Nature 2012, 491:254-258.
14. Yan A.W., Fouts D.E., Brandl J., et al. Enteric dysbiosis associated with a mouse model of alcoholic liver disease. Hepatology 2011, 53:96-105.
15. Zhu L., Baker S.S., Gill C., et al. Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: a connection between endogenous alcohol and NASH. Hepatology 2013, 57:601-609.
16. Chen P., Starkel P., Turner J.R., et al. Dysbiosis-induced intestinal inflammation activates tumor necrosis factor receptor I and mediates alcoholic liver disease in mice. Hepatology 2015, 61:883-894.
17. Turnbaugh P.J., Hamady M., Yatsunenko T., et al. Acore gut microbiome in obese and lean twins. Nature 2009, 457:480-484.
18. Jumpertz R., Le D.S., Turnbaugh P.J., et al. Energy-balance studies reveal associations between gut microbes, caloric load, and nutrient absorption in humans. Am J Clin Nutr 2011, 94:58-65.
19. Backhed F., Ding H., Wang T., et al. The gut microbiota as an environmental factor that regulates fat storage. Proc Natl Acad Sci USA 2004, 101:15718-15723.
20. Leclercq S., Matamoros S., Cani P.D., et al. Intestinal permeability, gut-bacterial dysbiosis, and behavioral markers of alcohol-dependence severity. Proc Natl Acad Sci USA 2014, 111:E4485-E4493.
21. Bode J.C., Bode C., Heidelbach R., et al. Jejunal microflora in patients with chronic alcohol abuse. Hepatogastroenterology 1984, 31:30-34.
22. Mutlu E.A., Gillevet P.M., Rangwala H., et al. Colonic microbiome is altered in alcoholism. Am J Physiol Gastrointest Liver Physiol 2012, 302:G966-G978.
23. Mutlu E., Keshavarzian A., Engen P., et al. Intestinal dysbiosis: a possible mechanism of alcohol-induced endotoxemia and alcoholic steatohepatitis in rats. Alcohol Clin Exp Res 2009, 33:1836-1846.
24. Bull-Otterson L., Feng W., Kirpich I., et al. Metagenomic analyses of alcohol induced pathogenic alterations in the intestinal microbiome and the effect of Lactobacillus rhamnosus GG treatment. PloS One 2013, 8:e53028.
25. Chen P., Torralba M., Tan J., et al. Supplementation of saturated long-chain fatty acids maintains intestinal eubiosis and reduces ethanol-induced liver injury in mice. Gastroenterology 2015, 148:203-214 e216.
26. Wang Y., Kirpich I., Liu Y., et al. Lactobacillus rhamnosus GG treatment potentiates intestinal hypoxia-inducible factor, promotes intestinal integrity and ameliorates alcohol-induced liver injury. Am J Pathol 2011, 179:2866-2875.
27. Brandl K., Plitas G., Mihu C.N., et al. Vancomycin-resistant enterococci exploit antibiotic-induced innate immune deficits. Nature 2008, 455:804-807.
28. Cho I., Yamanishi S., Cox L., et al. Antibiotics in early life alter the murine colonic microbiome and adiposity. Nature 2012, 488:621-626.
29. Hildebrand H., Malmborg P., Askling J., et al. Early-life exposures associated with antibiotic use and risk of subsequent Crohn's disease. Scand J Gastroenterol 2008, 43:961-966.
30. Card T., Logan R.F., Rodrigues L.C., et al. Antibiotic use and the development of Crohn's disease. Gut 2004, 53:246-250.
31. Gilat T., Hacohen D., Lilos P., Langman M.J. Childhood factors in ulcerative colitis and Crohn's disease: an international cooperative study. Scand J Gastroenterol 1987, 22:1009-1024.
32. Dominguez-Bello M.G., Costello E.K., Contreras M., et al. Delivery mode shapes the acquisition and structure of the initial microbiota across multiple body habitats in newborns. Proc Natl Acad Sci USA 2010, 107:11971-11975.
33. Charlson E.S., Chen J., Custers-Allen R., et al. Disordered microbial communities in the upper respiratory tract of cigarette smokers. PloS One 2010, 5:e15216.
34. Benjamin J.L., Hedin C.R., Koutsoumpas A., et al. Smokers with active Crohn's disease have a clinically relevant dysbiosis of the gastrointestinal microbiota. Inflamm Bowel Dis 2012, 18:1092-1100.
35. Biedermann L., Zeitz J., Mwinyi J., et al. Smoking cessation induces profound changes in the composition of the intestinal microbiota in humans. PloS One 2013, 8:e59260.
36. Walk S.T., Blum A.M., Ewing S.A., et al. Alteration of the murine gut microbiota during infection with the parasitic helminth Heligmosomoides polygyrus. Inflamm Bowel Dis 2010, 16:1841-1849.
37. Lee S., Sung J., Lee J., et al. Comparison of the gut microbiotas of healthy adult twins living in South Korea and the United States. Appl Environ Microbiol 2011, 77:7433-7437.
38. Dicksved J., Halfvarson J., Rosenquist M., et al. Molecular analysis of the gut microbiota of identical twins with Crohn's disease. ISME J 2008, 2:716-727.
39. Benson A.K., Kelly S.A., Legge R., et al. Individuality in gut microbiota composition is a complex polygenic trait shaped by multiple environmental and host genetic factors. Proc Natl Acad Sci USA 2010, 107:18933-18938.
40. Goodrich J.K., Waters J.L., Poole A.C., et al. Human genetics shape the gut microbiome. Cell 2014, 159:789-799.
41. Knights D., Silverberg M.S., Weersma R.K., et al. Complex host genetics influence the microbiome in inflammatory bowel disease. Genome Med 2014, 6:107.
42. Bruns T., Peter J., Reuken P.A., et al. NOD2 gene variants are a risk factor for culture-positive spontaneous bacterial peritonitis and monomicrobial bacterascites in cirrhosis. Liver Int 2012, 32:223-230.
43. Appenrodt B., Grunhage F., Gentemann M.G., et al. Nucleotide-binding oligomerization domain containing 2 (NOD2) variants are genetic risk factors for death and spontaneous bacterial peritonitis in liver cirrhosis. Hepatology 2010, 51:1327-1333.
44. Saner F.H., Nowak K., Hoyer D., et al. Anon-interventional study of the genetic polymorphisms of NOD2 associated with increased mortality in non-alcoholic liver transplant patients. BMC Gastroenterol 2014, 14:4.
45. Elinav E., Strowig T., Kau A.L., et al. NLRP6 inflammasome regulates colonic microbial ecology and risk for colitis. Cell 2011, 145:745-757.
46. Henao-Mejia J., Elinav E., Jin C., et al. Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature 2012, 482:179-185.
47. Hedin C.R., McCarthy N.E., Louis P., et al. Altered intestinal microbiota and blood T cell phenotype are shared by patients with Crohn's disease and their unaffected siblings. Gut 2014, 63:1578-1586.
48. Hooper L.V., Littman D.R., Macpherson A.J. Interactions between the microbiota and the immune system. Science 2012, 336:1268-1273.
49. Swidsinski A., Sydora B.C., Doerffel Y., et al. Viscosity gradient within the mucus layer determines the mucosal barrier function and the spatial organization of the intestinal microbiota. Inflamm Bowel Dis 2007, 13:963-970.
50. Sommer F., Backhed F. The gut microbiota-masters of host development and physiology. Nat Rev Microbiol 2013, 11:227-238.
51. Yang D., Chertov O., Oppenheim J.J. Participation of mammalian defensins and cathelicidins in anti-microbial immunity: receptors and activities of human defensins and cathelicidin (LL-37). JLeukoc Biol 2001, 69:691-697.
52. Kubinak J.L., Petersen C., Stephens W.Z., et al. MyD88 Signaling in T cells directs IgA-mediated control of the microbiota to promote health. Cell Host Microbe 2015, 17:153-163.
53. Macpherson A.J., Gatto D., Sainsbury E., et al. Aprimitive T cell-independent mechanism of intestinal mucosal IgA responses to commensal bacteria. Science 2000, 288:2222-2226.
54. Kawamoto S., Tran T.H., Maruya M., et al. The inhibitory receptor PD-1 regulates IgA selection and bacterial composition in the gut. Science 2012, 336:485-489.
55. Petnicki-Ocwieja T., Hrncir T., Liu Y.J., et al. Nod2 is required for the regulation of commensal microbiota in the intestine. Proc Natl Acad Sci USA 2009, 106:15813-15818.
56. Salzman N.H., Hung K., Haribhai D., et al. Enteric defensins are essential regulators of intestinal microbial ecology. Nat Immunol 2010, 11:76-83.
57. Vaishnava S., Yamamoto M., Severson K.M., et al. The antibacterial lectin RegIIIgamma promotes the spatial segregation of microbiota and host in the intestine. Science 2011, 334:255-258.
58. Teltschik Z., Wiest R., Beisner J., et al. Intestinal bacterial translocation in rats with cirrhosis is related to compromised Paneth cell antimicrobial host defense. Hepatology 2012, 55:1154-1163.
59. Johansson M.E., Larsson J.M., Hansson G.C. The two mucus layers of colon are organized by the MUC2 mucin, whereas the outer layer is a legislator of host-microbial interactions. Proc Natl Acad Sci USA 2011, 108(Suppl 1):4659-4665.
60. Juge N. Microbial adhesins to gastrointestinal mucus. Trends Microbiol 2012, 20:30-39.
61. Derrien M., van Passel M.W., van de Bovenkamp J.H., et al. Mucin-bacterial interactions in the human oral cavity and digestive tract. Gut Microbes 2010, 1:254-268.
62. Zarepour M., Bhullar K., Montero M., et al. The mucin Muc2 limits pathogen burdens and epithelial barrier dysfunction during Salmonella enterica serovar Typhimurium colitis. Infect Immun 2013, 81:3672-3683.
63. Sovran B., Loonen L.M., Lu P., et al. IL-22-STAT3 pathway plays a key role in the maintenance of ileal homeostasis in mice lacking secreted mucus barrier. Inflamm Bowel Dis 2015, 21:531-542.
64. Qin N., Yang F., Li A., et al. Alterations of the human gut microbiome in liver cirrhosis. Nature 2014, 513:59-64.
65. Scobie B.A., Summerskill W.H. Reduced gastric acid output in cirrhosis: quantitation and relationships. Gut 1964, 5:422-428.
66. Lu H., Wu Z., Xu W., et al. Intestinal microbiota was assessed in cirrhotic patients with hepatitis B virus infection. Intestinal microbiota of HBV cirrhotic patients. Microb Ecol 2011, 61:693-703.
67. Schnabl B., Brenner D.A. Interactions between the intestinal microbiome and liver diseases. Gastroenterology 2014, 146:1513-1524.
68. Hartmann P., Seebauer C.T., Schnabl B. Alcoholic liver disease: the gut microbiome and liver crosstalk. Alcohol Clin Exp Res 2015, 39:763-775.
69. De Minicis S., Rychlicki C., Agostinelli L., et al. Dysbiosis contributes to fibrogenesis in the course of chronic liver injury in mice. Hepatology 2014, 59:1738-1749.
70. Cani P.D., Amar J., Iglesias M.A., et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 2007, 56:1761-1772.
71. Teixeira T.F., Souza N.C., Chiarello P.G., et al. Intestinal permeability parameters in obese patients are correlated with metabolic syndrome risk factors. Clin Nutr 2012, 31:735-740.
72. Miele L., Valenza V., La Torre G., et al. Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology 2009, 49:1877-1887.
73. Keshavarzian A., Fields J.Z., Vaeth J., Holmes E.W. The differing effects of acute and chronic alcohol on gastric and intestinal permeability. Am J Gastroenterol 1994, 89:2205-2211.
74. Pendyala S., Neff L.M., Suarez-Farinas M., Holt P.R. Diet-induced weight loss reduces colorectal inflammation: implications for colorectal carcinogenesis. Am J Clin Nutr 2011, 93:234-242.
75. Ding S., Chi M.M., Scull B.P., et al. High-fat diet: bacteria interactions promote intestinal inflammation which precedes and correlates with obesity and insulin resistance in mouse. PLoS One 2010, 5:e12191.
76. Amar J., Burcelin R., Ruidavets J.B., et al. Energy intake is associated with endotoxemia in apparently healthy men. Am J Clin Nutr 2008, 87:1219-1223.
77. Erridge C., Attina T., Spickett C.M., et al. Ahigh-fat meal induces low-grade endotoxemia: evidence of a novel mechanism of postprandial inflammation. Am J Clin Nutr 2007, 86:1286-1292.
78. Alisi A., Manco M., Devito R., et al. Endotoxin and plasminogen activator inhibitor-1 serum levels associated with nonalcoholic steatohepatitis in children. JPediatr Gastroenterol Nutr 2010, 50:645-649.
79. Farhadi A., Gundlapalli S., Shaikh M., et al. Susceptibility togut leakiness: a possible mechanism for endotoxaemia in non-alcoholic steatohepatitis. Liver Int 2008, 28:1026-1033.
80. Garcia-Tsao G., Lee F.Y., Barden G.E., et al. Bacterial translocation to mesenteric lymph nodes is increased in cirrhotic rats with ascites. Gastroenterology 1995, 108:1835-1841.
81. Saitoh O., Sugi K., Lojima K., et al. Increased prevalence of intestinal inflammation in patients with liver cirrhosis. World J Gastroenterol 1999, 5:391-396.
82. Du Plessis J., Vanheel H., Janssen C.E., et al. Activated intestinal macrophages in patients with cirrhosis release NO and IL-6 that may disrupt intestinal barrier function. JHepatol 2013, 58:1125-1132.
83. Wiest R., Lawson M., Geuking M. Reply to: "Bacterial translocation in liver cirrhosis: site and role in fibrogenesis". JHepatol 2014, 61:710-711.
84. Wiest R., Lawson M., Geuking M. Pathological bacterial translocation in liver cirrhosis. JHepatol 2014, 60:197-209.
85. Uesugi T., Froh M., Arteel G.E., et al. Toll-like receptor 4 is involved in the mechanism of early alcohol-induced liver injury in mice. Hepatology 2001, 34:101-108.
86. Hritz I., Mandrekar P., Velayudham A., et al. The critical role of toll-like receptor (TLR) 4 in alcoholic liver disease is independent of the common TLR adapter MyD88. Hepatology 2008, 48:1224-1231.
87. Seki E., De Minicis S., Osterreicher C.H., et al. TLR4 enhances TGF-beta signaling and hepatic fibrosis. Nat Med 2007, 13:1324-1332.
88. Hartmann P., Haimerl M., Mazagova M., et al. Toll-like receptor 2-mediated intestinal injury and enteric tumor necrosis factor receptor I contribute to liver fibrosis in mice. Gastroenterology 2012, 143:1330-1340 e1331.
89. Saberi M., Woods N.B., de Luca C., et al. Hematopoietic cell-specific deletion of toll-like receptor 4 ameliorates hepatic and adipose tissue insulin resistance in high-fat-fed mice. Cell Metab 2009, 10:419-429.
90. Miura K., Kodama Y., Inokuchi S., et al. Toll-like receptor 9promotes steatohepatitis by induction of interleukin-1 beta in mice. Gastroenterology 2010, 139:323-334 e327.
91. Rivera C.A., Adegboyega P., van Rooijen N., et al. Toll-like receptor-4 signaling and Kupffer cells play pivotal roles in the pathogenesis of non-alcoholic steatohepatitis. JHepatol 2007, 47:571-579.
92. Cani P.D., Bibiloni R., Knauf C., et al. Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. Diabetes 2008, 57:1470-1481.
93. Adachi Y., Moore L.E., Bradford B.U., et al. Antibiotics prevent liver injury in rats following long-term exposure to ethanol. Gastroenterology 1995, 108:218-224.
94. Douhara A., Moriya K., Yoshiji H., et al. Reduction of endotoxin attenuates liver fibrosis through suppression of hepatic stellate cell activation and remission of intestinal permeability in a rat non-alcoholic steatohepatitis model. Mol Med Rep 2015, 11:1693-1700.
95. Bode C., Schafer C., Fukui H., et al. Effect of treatment with paromomycin on endotoxemia in patients with alcoholic liver disease-a double-blind, placebo-controlled trial. Alcohol Clin Exp Res 1997, 21:1367-1373.
96. Bass N.M., Mullen K.D., Sanyal A., et al. Rifaximin treatment in hepatic encephalopathy. NEngl J Med 2010, 362:1071-1081.
97. Mazagova M., Wang L., Anfora A.T., et al. Commensal microbiota is hepatoprotective and prevents liver fibrosis in mice. FASEB J 2015, 29:1043-1055.
98. Wikoff W.R., Anfora A.T., Liu J., et al. Metabolomics analysis reveals large effects of gut microflora on mammalian blood metabolites. Proc Natl Acad Sci USA 2009, 106:3698-3703.
99. Venkatesh M., Mukherjee S., Wang H., et al. Symbiotic bacterial metabolites regulate gastrointestinal barrier function via the xenobiotic sensor PXR and Toll-like receptor 4. Immunity 2014, 41:296-310.
100. Abu-Shanab A., Quigley E.M. The role of the gut microbiota in nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol 2010, 7:691-701.
101. Hildebrandt M.A., Hoffmann C., Sherrill-Mix S.A., et al. High-fat diet determines the composition of the murine gut microbiome independently of obesity. Gastroenterology 2009, 137:1716-1724. e1-2.
102. Conterno L., Fava F., Viola R., et al. Obesity and the gut microbiota: does up-regulating colonic fermentation protect against obesity and metabolic disease?. Genes Nutr 2011, 6:241-260.
103. Backhed F., Manchester J.K., Semenkovich C.F., et al. Mechanisms underlying the resistance to diet-induced obesity in germ-free mice. Proc Natl Acad Sci USA 2007, 104:979-984.
104. Ridaura V.K., Faith J.J., Rey F.E., et al. Gut microbiota from twins discordant for obesity modulate metabolism in mice. Science 2013, 341:1241214.
105. Turnbaugh P.J., Ley R.E., Mahowald M.A., et al. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 2006, 444:1027-1031.
106. Nair S., Cope K., Risby T.H., et al. Obesity and female gender increase breath ethanol concentration: potential implications for the pathogenesis of nonalcoholic steatohepatitis. Am J Gastroenterol 2001, 96:1200-1204.
107. Cope K., Risby T., Diehl A.M. Increased gastrointestinal ethanol production in obese mice: implications for fatty liver disease pathogenesis. Gastroenterology 2000, 119:1340-1347.
108. Hartmann P., Chen W.C., Schnabl B. The intestinal microbiome and the leaky gut as therapeutic targets in alcoholic liver disease. Front Physiol 2012, 3:402.
109. Jokelainen K., Roine R.P., Vaananen H., et al. Invitro acetaldehyde formation by human colonic bacteria. Gut 1994, 35:1271-1274.
110. Abdelmegeed M.A., Banerjee A., Jang S., et al. CYP2E1 potentiates binge alcohol-induced gut leakiness, steatohepatitis, and apoptosis. Free Radic Biol Med 2013, 65:1238-1245.
111. Forsyth C.B., Voigt R.M., Shaikh M., et al. Role for intestinal CYP2E1 in alcohol-induced circadian gene-mediated intestinal hyperpermeability. Am J Physiol Gastrointest Liver Physiol 2013, 305:G185-G195.
112. Rao R.K. Acetaldehyde-induced barrier disruption and paracellular permeability in Caco-2 cell monolayer. Methods Mol Biol 2008, 447:171-183.
113. Dumas M.E., Barton R.H., Toye A., et al. Metabolic profiling reveals a contribution of gut microbiota to fatty liver phenotype in insulin-resistant mice. Proc Natl Acad Sci USA 2006, 103:12511-12516.
114. Jiang X.C., Li Z., Liu R., et al. Phospholipid transfer protein deficiency impairs apolipoprotein-B secretion from hepatocytes by stimulating a proteolytic pathway through a relative deficiency of vitamin E and an increase in intracellular oxidants. JBiol Chem 2005, 280:18336-18340.
115. Blumberg H., McCollum E.V. The prevention by choline of liver cirrhosis in rats on high fat, low protein diets. Science 1941, 93:598-599.
116. Spencer M.D., Hamp T.J., Reid R.W., et al. Association between composition of the human gastrointestinal microbiome and development of fatty liver with choline deficiency. Gastroenterology 2011, 140:976-986.
117. Rehman A., Sina C., Gavrilova O., et al. Nod2 is essential for temporal development of intestinal microbial communities. Gut 2011, 60:1354-1362.